Ontology highlight
ABSTRACT:
SUBMITTER: Schramm A
PROVIDER: S-EPMC4569208 | biostudies-literature | 2015 Jul
REPOSITORIES: biostudies-literature
Schramm Amelie A De Gregorio Nikolaus N Widschwendter Peter P Fink Visnja V Huober Jens J
Breast care (Basel, Switzerland) 20150618 3
About 20% of all breast cancer patients have a human epidermal growth factor receptor 2 (HER2)-positive breast tumor. This entity underwent an impressive change in prognosis, with notable improvement of progression-free survival and overall survival. Due to more aggressive tumors and no specific therapy, HER2 overexpression was historically seen as a negative prognostic marker, with worse prognosis and increased risk of recurrent disease. Trastuzumab, the first anti-HER2 antibody, revolutionized ...[more]